CA2001790A1 - Compositions pharmaceutiques et leur utilisation - Google Patents

Compositions pharmaceutiques et leur utilisation

Info

Publication number: CA2001790A1
Authority: CA; Canada
Prior art keywords: treatment; composition; derivative; fusidic acid; manufacture
Prior art date: 1988-10-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002001790A

Other languages

English (en)

Inventor

Klaus Bendtzen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-28

Filing date

1989-10-30

Publication date

1990-04-28

1989-10-30 Application filed by Individual filed Critical Individual

1990-04-28 Publication of CA2001790A1 publication Critical patent/CA2001790A1/fr

Status Abandoned legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims abstract description 184
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims abstract description 106
238000004519 manufacturing process Methods 0.000 claims abstract description 106
239000000203 mixture Substances 0.000 claims abstract description 104
229960004675 fusidic acid Drugs 0.000 claims abstract description 102
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 65
102000004127 Cytokines Human genes 0.000 claims abstract description 63
108090000695 Cytokines Proteins 0.000 claims abstract description 63
201000010099 disease Diseases 0.000 claims abstract description 50
206010003246 arthritis Diseases 0.000 claims abstract description 31
208000011231 Crohn disease Diseases 0.000 claims abstract description 17
206010046851 Uveitis Diseases 0.000 claims abstract description 17
206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 16
230000003405 preventing effect Effects 0.000 claims abstract description 13
210000001685 thyroid gland Anatomy 0.000 claims abstract description 12
208000034578 Multiple myelomas Diseases 0.000 claims abstract description 11
206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 10
201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 10
241000894006 Bacteria Species 0.000 claims abstract description 9
238000001356 surgical procedure Methods 0.000 claims abstract description 9
206010043778 thyroiditis Diseases 0.000 claims abstract description 9
208000002177 Cataract Diseases 0.000 claims abstract description 8
230000001613 neoplastic effect Effects 0.000 claims abstract description 8
238000002054 transplantation Methods 0.000 claims abstract description 8
206010040070 Septic Shock Diseases 0.000 claims abstract description 7
206010052779 Transplant rejections Diseases 0.000 claims abstract description 7
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 7
230000036303 septic shock Effects 0.000 claims abstract description 7
206010034277 Pemphigoid Diseases 0.000 claims abstract description 6
206010047115 Vasculitis Diseases 0.000 claims abstract description 6
210000004087 cornea Anatomy 0.000 claims abstract description 6
206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 5
208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 5
201000008482 osteoarthritis Diseases 0.000 claims abstract description 5
201000008937 atopic dermatitis Diseases 0.000 claims abstract 8
206010012442 Dermatitis contact Diseases 0.000 claims abstract 7
208000010247 contact dermatitis Diseases 0.000 claims abstract 7
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims abstract 6
201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 6
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims abstract 6
208000015943 Coeliac disease Diseases 0.000 claims abstract 4
206010012434 Dermatitis allergic Diseases 0.000 claims abstract 4
206010012438 Dermatitis atopic Diseases 0.000 claims abstract 4
201000011152 Pemphigus Diseases 0.000 claims abstract 4
230000000172 allergic effect Effects 0.000 claims abstract 4
208000010668 atopic eczema Diseases 0.000 claims abstract 4
238000002430 laser surgery Methods 0.000 claims abstract 4
201000001976 pemphigus vulgaris Diseases 0.000 claims abstract 4
208000028169 periodontal disease Diseases 0.000 claims abstract 4
208000007048 Polymyalgia Rheumatica Diseases 0.000 claims abstract 3
208000031845 Pernicious anaemia Diseases 0.000 claims abstract 2
238000011282 treatment Methods 0.000 claims description 174
238000000034 method Methods 0.000 claims description 89
238000011321 prophylaxis Methods 0.000 claims description 54
239000002253 acid Substances 0.000 claims description 51
210000001744 T-lymphocyte Anatomy 0.000 claims description 45
206010012601 diabetes mellitus Diseases 0.000 claims description 35
230000002265 prevention Effects 0.000 claims description 35
108010036949 Cyclosporine Proteins 0.000 claims description 24
230000001154 acute effect Effects 0.000 claims description 24
229960001265 ciclosporin Drugs 0.000 claims description 24
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 23
229930105110 Cyclosporin A Natural products 0.000 claims description 22
239000003889 eye drop Substances 0.000 claims description 17
208000035475 disorder Diseases 0.000 claims description 14
230000001684 chronic effect Effects 0.000 claims description 13
230000037396 body weight Effects 0.000 claims description 12
201000007497 subacute thyroiditis Diseases 0.000 claims description 10
230000004071 biological effect Effects 0.000 claims description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
208000003950 B-cell lymphoma Diseases 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 7
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
239000003885 eye ointment Substances 0.000 claims description 6
208000024908 graft versus host disease Diseases 0.000 claims description 6
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
230000000699 topical effect Effects 0.000 claims description 6
206010061218 Inflammation Diseases 0.000 claims description 5
208000033464 Reiter syndrome Diseases 0.000 claims description 5
230000004054 inflammatory process Effects 0.000 claims description 5
238000002347 injection Methods 0.000 claims description 5
239000007924 injection Substances 0.000 claims description 5
239000006210 lotion Substances 0.000 claims description 5
201000005962 mycosis fungoides Diseases 0.000 claims description 5
208000002574 reactive arthritis Diseases 0.000 claims description 5
208000026872 Addison Disease Diseases 0.000 claims description 4
208000032467 Aplastic anaemia Diseases 0.000 claims description 4
208000023328 Basedow disease Diseases 0.000 claims description 4
208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 4
208000016192 Demyelinating disease Diseases 0.000 claims description 4
208000015023 Graves' disease Diseases 0.000 claims description 4
206010021067 Hypopituitarism Diseases 0.000 claims description 4
208000009525 Myocarditis Diseases 0.000 claims description 4
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
206010039710 Scleroderma Diseases 0.000 claims description 4
206010043784 Thyroiditis subacute Diseases 0.000 claims description 4
230000002062 proliferating effect Effects 0.000 claims description 4
201000000306 sarcoidosis Diseases 0.000 claims description 4
206010008909 Chronic Hepatitis Diseases 0.000 claims description 3
239000004471 Glycine Substances 0.000 claims description 3
206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
208000025747 Rheumatic disease Diseases 0.000 claims description 3
229960003080 taurine Drugs 0.000 claims description 3
208000000112 Myalgia Diseases 0.000 claims description 2
239000003018 immunosuppressive agent Substances 0.000 claims description 2
229940124589 immunosuppressive drug Drugs 0.000 claims description 2
238000002513 implantation Methods 0.000 claims description 2
230000000552 rheumatic effect Effects 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims 7
208000030836 Hashimoto thyroiditis Diseases 0.000 claims 6
206010043782 Thyroiditis fibrous chronic Diseases 0.000 claims 6
210000003563 lymphoid tissue Anatomy 0.000 claims 5
208000010266 Aggressive Periodontitis Diseases 0.000 claims 3
208000033222 Biliary cirrhosis primary Diseases 0.000 claims 3
206010060742 Endocrine ophthalmopathy Diseases 0.000 claims 3
206010015226 Erythema nodosum Diseases 0.000 claims 3
208000007465 Giant cell arteritis Diseases 0.000 claims 3
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 3
208000001204 Hashimoto Disease Diseases 0.000 claims 3
101000687911 Homo sapiens Transcription factor SOX-3 Proteins 0.000 claims 3
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 3
208000012654 Primary biliary cholangitis Diseases 0.000 claims 3
208000009359 Sezary Syndrome Diseases 0.000 claims 3
208000021386 Sjogren Syndrome Diseases 0.000 claims 3
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 3
102100024276 Transcription factor SOX-3 Human genes 0.000 claims 3
210000004100 adrenal gland Anatomy 0.000 claims 3
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 3
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 3
208000009190 disseminated intravascular coagulation Diseases 0.000 claims 3
210000004907 gland Anatomy 0.000 claims 3
201000009958 panhypopituitarism Diseases 0.000 claims 3
201000001245 periodontitis Diseases 0.000 claims 3
201000006727 periodontosis Diseases 0.000 claims 3
201000006292 polyarteritis nodosa Diseases 0.000 claims 3
208000005987 polymyositis Diseases 0.000 claims 3
201000007540 subacute lymphocytic thyroiditis Diseases 0.000 claims 3
206010043207 temporal arteritis Diseases 0.000 claims 3
208000007502 anemia Diseases 0.000 claims 2
239000007972 injectable composition Substances 0.000 claims 2
208000014997 Crohn colitis Diseases 0.000 claims 1
150000001242 acetic acid derivatives Chemical class 0.000 claims 1
239000000032 diagnostic agent Substances 0.000 claims 1
238000011200 topical administration Methods 0.000 claims 1
-1 e lymphokine Proteins 0.000 abstract description 14
102000015696 Interleukins Human genes 0.000 abstract description 8
108010063738 Interleukins Proteins 0.000 abstract description 8
102000014150 Interferons Human genes 0.000 abstract description 6
108010050904 Interferons Proteins 0.000 abstract description 6
229940079322 interferon Drugs 0.000 abstract description 5
108010071942 Colony-Stimulating Factors Proteins 0.000 abstract description 4
102000007644 Colony-Stimulating Factors Human genes 0.000 abstract description 4
230000002452 interceptive effect Effects 0.000 abstract description 4
230000001575 pathological effect Effects 0.000 abstract description 3
210000004027 cell Anatomy 0.000 description 93
230000000694 effects Effects 0.000 description 91
102000004889 Interleukin-6 Human genes 0.000 description 83
108090001005 Interleukin-6 Proteins 0.000 description 83
HJHVQCXHVMGZNC-JCJNLNMISA-M sodium;(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate Chemical compound [Na+].O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C HJHVQCXHVMGZNC-JCJNLNMISA-M 0.000 description 81
229940100601 interleukin-6 Drugs 0.000 description 79
229940079593 drug Drugs 0.000 description 40
239000003814 drug Substances 0.000 description 40
230000006870 function Effects 0.000 description 35
238000012360 testing method Methods 0.000 description 34
102100040247 Tumor necrosis factor Human genes 0.000 description 31
238000002560 therapeutic procedure Methods 0.000 description 31
210000004369 blood Anatomy 0.000 description 26
239000008280 blood Substances 0.000 description 26
150000002500 ions Chemical class 0.000 description 25
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
102000000589 Interleukin-1 Human genes 0.000 description 21
108010002352 Interleukin-1 Proteins 0.000 description 21
108010002350 Interleukin-2 Proteins 0.000 description 18
102000000588 Interleukin-2 Human genes 0.000 description 18
229930182912 cyclosporin Natural products 0.000 description 18
230000004044 response Effects 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 15
239000000427 antigen Substances 0.000 description 13
102000036639 antigens Human genes 0.000 description 13
108091007433 antigens Proteins 0.000 description 13
239000002158 endotoxin Substances 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
210000003719 b-lymphocyte Anatomy 0.000 description 12
210000000988 bone and bone Anatomy 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
102000004877 Insulin Human genes 0.000 description 11
108090001061 Insulin Proteins 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
229940125396 insulin Drugs 0.000 description 11
230000003389 potentiating effect Effects 0.000 description 11
230000008569 process Effects 0.000 description 11
210000002966 serum Anatomy 0.000 description 11
230000009471 action Effects 0.000 description 10
108010013381 Porins Proteins 0.000 description 9
239000012190 activator Substances 0.000 description 9
230000012010 growth Effects 0.000 description 9
229940088597 hormone Drugs 0.000 description 9
239000005556 hormone Substances 0.000 description 9
230000001965 increasing effect Effects 0.000 description 9
210000004698 lymphocyte Anatomy 0.000 description 9
102000007739 porin activity proteins Human genes 0.000 description 9
230000004913 activation Effects 0.000 description 8
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
230000002458 infectious effect Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
239000003826 tablet Substances 0.000 description 8
238000003556 assay Methods 0.000 description 7
210000002421 cell wall Anatomy 0.000 description 7
230000001413 cellular effect Effects 0.000 description 7
210000002950 fibroblast Anatomy 0.000 description 7
239000003862 glucocorticoid Substances 0.000 description 7
210000004408 hybridoma Anatomy 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 7
229920006008 lipopolysaccharide Polymers 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
210000003491 skin Anatomy 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
102000008072 Lymphokines Human genes 0.000 description 6
108010074338 Lymphokines Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
108700012920 TNF Proteins 0.000 description 6
QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 6
230000007717 exclusion Effects 0.000 description 6
229940012356 eye drops Drugs 0.000 description 6
239000008103 glucose Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
201000000050 myeloid neoplasm Diseases 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
206010037660 Pyrexia Diseases 0.000 description 5
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
230000036765 blood level Effects 0.000 description 5
210000001185 bone marrow Anatomy 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 5
229910052717 sulfur Inorganic materials 0.000 description 5
230000003442 weekly effect Effects 0.000 description 5
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
229940109239 creatinine Drugs 0.000 description 4
231100000673 dose–response relationship Toxicity 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
229940048400 fucidin Drugs 0.000 description 4
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
210000004124 hock Anatomy 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
206010025135 lupus erythematosus Diseases 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
229960005205 prednisolone Drugs 0.000 description 4
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
230000035939 shock Effects 0.000 description 4
241000894007 species Species 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
229940037128 systemic glucocorticoids Drugs 0.000 description 4
230000001960 triggered effect Effects 0.000 description 4
230000004304 visual acuity Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
208000006386 Bone Resorption Diseases 0.000 description 3
241000518994 Conta Species 0.000 description 3
241000501458 Cultus Species 0.000 description 3
240000003550 Eusideroxylon zwageri Species 0.000 description 3
208000010201 Exanthema Diseases 0.000 description 3
108010051539 HLA-DR2 Antigen Proteins 0.000 description 3
101150093335 KIN1 gene Proteins 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241001163743 Perlodes Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
239000002269 analeptic agent Substances 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
125000003710 aryl alkyl group Chemical group 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000011443 conventional therapy Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
201000005884 exanthem Diseases 0.000 description 3
GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
239000000411 inducer Substances 0.000 description 3
230000003902 lesion Effects 0.000 description 3
210000005087 mononuclear cell Anatomy 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000003921 oil Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
206010037844 rash Diseases 0.000 description 3
239000011734 sodium Substances 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
101150034533 ATIC gene Proteins 0.000 description 2
206010048998 Acute phase reaction Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
108010028780 Complement C3 Proteins 0.000 description 2
102000016918 Complement C3 Human genes 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
241000448280 Elates Species 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
206010015150 Erythema Diseases 0.000 description 2
206010015958 Eye pain Diseases 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
108010058597 HLA-DR Antigens Proteins 0.000 description 2
102000006354 HLA-DR Antigens Human genes 0.000 description 2
102000014702 Haptoglobin Human genes 0.000 description 2
108050005077 Haptoglobin Proteins 0.000 description 2
101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
241000489861 Maximus Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
208000037273 Pathologic Processes Diseases 0.000 description 2
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
241000219061 Rheum Species 0.000 description 2
108700028909 Serum Amyloid A Proteins 0.000 description 2
102000054727 Serum Amyloid A Human genes 0.000 description 2
101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 2
101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 2
101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 2
101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 2
101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 2
101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 2
101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
108091008874 T cell receptors Proteins 0.000 description 2
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
206010042971 T-cell lymphoma Diseases 0.000 description 2
102100036407 Thioredoxin Human genes 0.000 description 2
102000018594 Tumour necrosis factor Human genes 0.000 description 2
108050007852 Tumour necrosis factor Proteins 0.000 description 2
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
230000002411 adverse Effects 0.000 description 2
QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 2
230000000961 alloantigen Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
230000035602 clotting Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
231100000321 erythema Toxicity 0.000 description 2
238000013100 final test Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
230000000495 immunoinflammatory effect Effects 0.000 description 2
230000008676 import Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
238000011835 investigation Methods 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000003908 liver function Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
230000009054 pathological process Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
235000009991 pite Nutrition 0.000 description 2
244000293655 pite Species 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
201000001474 proteinuria Diseases 0.000 description 2
230000001185 psoriatic effect Effects 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000013049 sediment Substances 0.000 description 2
RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
235000005282 vitamin D3 Nutrition 0.000 description 2
239000011647 vitamin D3 Substances 0.000 description 2
229940021056 vitamin d3 Drugs 0.000 description 2
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
PLFFHJWXOGYWPR-HEDMGYOXSA-N (4r)-4-[(3r,3as,5ar,5br,7as,11as,11br,13ar,13bs)-5a,5b,8,8,11a,13b-hexamethyl-1,2,3,3a,4,5,6,7,7a,9,10,11,11b,12,13,13a-hexadecahydrocyclopenta[a]chrysen-3-yl]pentan-1-ol Chemical compound C([C@]1(C)[C@H]2CC[C@H]34)CCC(C)(C)[C@@H]1CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@@H]1[C@@H](CCCO)C PLFFHJWXOGYWPR-HEDMGYOXSA-N 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
CXENHBSYCFFKJS-OXYODPPFSA-N (Z,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(\C)C=C CXENHBSYCFFKJS-OXYODPPFSA-N 0.000 description 1
OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
NJXWZWXCHBNOOG-UHFFFAOYSA-N 3,3-diphenylpropyl(1-phenylethyl)azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(C)[NH2+]CCC(C=1C=CC=CC=1)C1=CC=CC=C1 NJXWZWXCHBNOOG-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
101150010783 Aard gene Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000011767 Acute-Phase Proteins Human genes 0.000 description 1
108010062271 Acute-Phase Proteins Proteins 0.000 description 1
241000270730 Alligator mississippiensis Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
244000118350 Andrographis paniculata Species 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
206010004659 Biliary cirrhosis Diseases 0.000 description 1
101710125089 Bindin Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
206010061728 Bone lesion Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
108010074051 C-Reactive Protein Proteins 0.000 description 1
102100032752 C-reactive protein Human genes 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
101100168093 Caenorhabditis elegans cogc-2 gene Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000543381 Cliftonia monophylla Species 0.000 description 1
102100024484 Codanin-1 Human genes 0.000 description 1
241001550206 Colla Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000000503 Collagen Type II Human genes 0.000 description 1
108010041390 Collagen Type II Proteins 0.000 description 1
108010078546 Complement C5a Proteins 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
241000283014 Dama Species 0.000 description 1
208000034423 Delivery Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
101100332286 Dictyostelium discoideum dst1 gene Proteins 0.000 description 1
101100366888 Dictyostelium discoideum dstA gene Proteins 0.000 description 1
101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
101100507451 Drosophila melanogaster sip3 gene Proteins 0.000 description 1
238000005773 Enders reaction Methods 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
210000000712 G cell Anatomy 0.000 description 1
101100042793 Gallus gallus SMC2 gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101150087426 Gnal gene Proteins 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000910494 Heth Species 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
101000980888 Homo sapiens Codanin-1 Proteins 0.000 description 1
101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
241001174911 Iasis Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
244000199265 Inga micheliana Species 0.000 description 1
235000012603 Inga micheliana Nutrition 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
102100026019 Interleukin-6 Human genes 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
101000941450 Lasioglossum laticeps Lasioglossin-1 Proteins 0.000 description 1
241000239218 Limulus Species 0.000 description 1
108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
241000332699 Moneses Species 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
241000269777 Mugilidae Species 0.000 description 1
101100490488 Mus musculus Add3 gene Proteins 0.000 description 1
101100059652 Mus musculus Cetn1 gene Proteins 0.000 description 1
101100059655 Mus musculus Cetn2 gene Proteins 0.000 description 1
101100221487 Mus musculus Cog2 gene Proteins 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
101100521130 Mus musculus Prelid1 gene Proteins 0.000 description 1
101100046790 Mus musculus Trappc2 gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
241000669618 Nothes Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
240000008881 Oenanthe javanica Species 0.000 description 1
108010061952 Orosomucoid Proteins 0.000 description 1
102000012404 Orosomucoid Human genes 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000015731 Peptide Hormones Human genes 0.000 description 1
108010038988 Peptide Hormones Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000791420 Plica Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
101100409194 Rattus norvegicus Ppargc1b gene Proteins 0.000 description 1
208000035999 Recurrence Diseases 0.000 description 1
206010038848 Retinal detachment Diseases 0.000 description 1
101100408472 Rhodocybe pseudopiperita ple6 gene Proteins 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
241000364027 Sinoe Species 0.000 description 1
241000708948 Solva Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241001611093 Stimula Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
101150083547 TESC gene Proteins 0.000 description 1
241000893638 Taractes Species 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
241000405217 Viola <butterfly> Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
241000289690 Xenarthra Species 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
230000008578 acute process Effects 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
230000001270 agonistic effect Effects 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
230000001494 anti-thymocyte effect Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
230000003286 arthritogenic effect Effects 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
230000003139 buffering effect Effects 0.000 description 1
229960005084 calcitriol Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000000837 carbohydrate group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002281 colonystimulating effect Effects 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
JNSGIVNNHKGGRU-JYRVWZFOSA-N diethoxyphosphinothioyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound CCOP(=S)(OCC)OC(=O)C(=N/OC)\C1=CSC(N)=N1 JNSGIVNNHKGGRU-JYRVWZFOSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
KOWWOODYPWDWOJ-LVBPXUMQSA-N elatine Chemical compound C([C@]12CN(C3[C@@]45OCO[C@]44[C@H]6[C@@H](OC)[C@@H]([C@H](C4)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]5OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O KOWWOODYPWDWOJ-LVBPXUMQSA-N 0.000 description 1
229940037395 electrolytes Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
238000013534 fluorescein angiography Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000001280 germinal center Anatomy 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
208000027700 hepatic dysfunction Diseases 0.000 description 1
102000052611 human IL6 Human genes 0.000 description 1
239000003906 humectant Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
QFGMXJOBTNZHEL-UHFFFAOYSA-N isoxepac Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(CC(=O)O)=CC=C21 QFGMXJOBTNZHEL-UHFFFAOYSA-N 0.000 description 1
229950011455 isoxepac Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000000629 knee joint Anatomy 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000002664 langerhans' cell Anatomy 0.000 description 1
101150085091 lat-2 gene Proteins 0.000 description 1
230000007775 late Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
206010024378 leukocytosis Diseases 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000000865 liniment Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000001699 lithographically induced self-assembly Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000032630 lymph circulation Effects 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000015689 metaplastic ossification Effects 0.000 description 1
STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000013586 microbial product Substances 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000002320 montanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000003387 muscular Effects 0.000 description 1
208000009091 myxoma Diseases 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
231100000028 nontoxic concentration Toxicity 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
230000003349 osteoarthritic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
206010035485 plasmacytosis Diseases 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
108010080511 serum sodium transport inhibitor Proteins 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
238000007390 skin biopsy Methods 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
239000000344 soap Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002301 subretinal fluid Anatomy 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
208000008732 thymoma Diseases 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000024664 tolerance induction Effects 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/003—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0027—Azides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)

CA002001790A 1988-10-28 1989-10-30 Compositions pharmaceutiques et leur utilisation Abandoned CA2001790A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK603988A DK603988D0 (da)	1988-10-28	1988-10-28	Farmaceutisk praeparat
DK6039/88		1988-10-28

Publications (1)

Publication Number	Publication Date
CA2001790A1 true CA2001790A1 (fr)	1990-04-28

Family

ID=8146989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002001790A Abandoned CA2001790A1 (fr)	1988-10-28	1989-10-30	Compositions pharmaceutiques et leur utilisation

Country Status (5)

Country	Link
EP (1)	EP0561772A1 (fr)
JP (1)	JPH05502434A (fr)
CA (1)	CA2001790A1 (fr)
DK (1)	DK603988D0 (fr)
WO (1)	WO1990004398A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9017677B2 (en)	1997-03-21	2015-04-28	Chugai Seiyaku Kabushiki Kaisha	Methods of treating a disease mediated by sensitized T cells

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5643901A (en) *	1990-06-11	1997-07-01	Fujisawa Pharmaceutical Co., Ltd.	Medicament for treating idiopathic thrombocytopenic purpura
WO1991019495A1 (fr) *	1990-06-11	1991-12-26	Fujisawa Pharmaceutical Co., Ltd.	Utilisation d'un compose de macrolide tel que le fk 506 pour fabriquer un medicament destine a traiter la purpura thrombocytopenique idiopathique et la maladie de basedow
GB2252041A (en) *	1991-01-23	1992-07-29	Fujisawa Pharmaceutical Co	Use of macrolide compounds in treatment of autoimmune myocarditis
US6046185A (en)	1996-07-11	2000-04-04	Inflazyme Pharmaceuticals Ltd.	6,7-oxygenated steroids and uses related thereto
EP1304333A3 (fr) *	1996-07-11	2005-03-09	Inflazyme Pharmaceuticals, Ltd.	Stéroides oxygénés en position 6,7 et leurs utilisations
WO2003027256A2 (fr) *	2001-09-27	2003-04-03	The Wistar Institute	Procedes et compositions pour surveiller la migration cellulaire et identifier l'activite cytotoxique des lymphocytes t a prendre en compte sur le plan clinique
WO2009038684A1 (fr) *	2007-09-14	2009-03-26	Biogen Idec Ma Inc.	Compositions et procédés de traitement de la leucoencéphalopathie multifocale progressive (lemp)
RU2536252C2 (ru) *	2008-12-19	2014-12-20	Сулур Субраманиам ВАНАНГАМУДИ	Новый дерматологический крем, изготовленный с использованием фусидата натрия
JP2012517995A (ja) *	2009-02-18	2012-08-09	スラーサブラマニアンヴァナンガムディ	フシジン酸ナトリウムを用いて作製した皮膚用医薬品ゲルおよびその作製方法
PL2419087T3 (pl) *	2009-04-13	2013-06-28	Vanangamudi Subramaniam Sulur	Leczniczy krem z kwasem fusydowym wytworzony z użyciem fusydanu sodu i wprowadzeniem biopolimeru i sposób jego wytwarzania
CN106749475B (zh) *	2017-01-13	2018-11-23	广东工业大学	一种夫西地酸化学修饰物的制备及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL7411402A (nl) *	1973-09-13	1975-03-17	Leo Pharm Prod Ltd	Werkwijze voor het bereiden van een middel tegen arthritis.
GB1490852A (en) *	1974-09-12	1977-11-02	Leo Pharm Prod Ltd	Fusidic acid derivatives
GB8706313D0 (en) *	1987-03-17	1987-04-23	Health Lab Service Board	Treatment & prevention of viral infections

1988
- 1988-10-28 DK DK603988A patent/DK603988D0/da not_active Application Discontinuation
1989
- 1989-10-30 CA CA002001790A patent/CA2001790A1/fr not_active Abandoned
- 1989-10-30 WO PCT/DK1989/000254 patent/WO1990004398A1/fr not_active Ceased
- 1989-10-30 EP EP89912408A patent/EP0561772A1/fr not_active Ceased
- 1989-10-30 JP JP1511635A patent/JPH05502434A/ja active Pending

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9017677B2 (en)	1997-03-21	2015-04-28	Chugai Seiyaku Kabushiki Kaisha	Methods of treating a disease mediated by sensitized T cells

Also Published As

Publication number	Publication date
JPH05502434A (ja)	1993-04-28
WO1990004398A1 (fr)	1990-05-03
EP0561772A1 (fr)	1993-09-29
DK603988D0 (da)	1988-10-28

Publication	Publication Date	Title
Reem et al.	1983	Gamma interferon synthesis by human thymocytes and T lymphocytes inhibited by cyclosporin A
Shevach	1985	The effects of cyclosporin A on the immune system.
Todd et al.	1985	Interferon-gamma induces HLA-DR expression by thyroid epithelium
Hu et al.	2013	Mesenchymal stem cells attenuate ischemic acute kidney injury by inducing regulatory T cells through splenocyte interactions
KR100623104B1 (ko)	2006-09-15	감마-글루타밀 및 베타-아스파르틸을 함유하는 면역조절화합물 및 그의 제조 방법
Barr	1986	Dermatologic applications of cyclosporine
Paltsev et al.	2016	Morphofunctional and signaling molecules overlap of the pineal gland and thymus: role and significance in aging
US6224859B1 (en)	2001-05-01	Composition containing immature mammalian dendritic cells for enhancing tolerogenicity to foreign graft
JP2547162B2 (ja)	1996-10-23	哺乳動物における異系移植片拒否反応を抑制するための方法と組成物
HU214326B (hu)	1998-03-02	Eljárás felnőtt T-sejt leukémia/limfóma kezelésére alkalmas gyógyszerkészítmények előállítására
CA2001790A1 (fr)	1990-04-28	Compositions pharmaceutiques et leur utilisation
WO2007048847A2 (fr)	2007-05-03	Derives indole et azaindole destines au traitement de maladies inflammatoires et autoimmunes
WO2012056344A1 (fr)	2012-05-03	Utilisation d'une composition constituée de spironolactone, qui présente une action inhibitrice de l'activation de lymphocytes t utiles dans la prévention et/ou le traitement de la sclérose en plaques
US20020150582A1 (en)	2002-10-17	Method of treating or inhibiting cellular injury or cell death
US20070244038A1 (en)	2007-10-18	Methods for treating lymphocyte-associated disorders by modulation of siglec activity
EA008946B1 (ru)	2007-10-26	Применение ингибиторов аланиламинопептидаз и содержащие их фармацевтические композиции
Walsh et al.	1991	Effects of cetirizine on human eosinophil and neutrophil activation in vitro
PT2120919E (pt)	2012-11-12	Nova combinação para utilização no tratamento de perturbações inflamatórias
Thomas et al.	2001	THIS ARTICLE HAS BEEN RETRACTED STEALTH matters: a novel paradigm of durable primate allograft tolerance
CA2255856C (fr)	2008-05-13	Utilisations therapeutiques d'un compose d'aminosterol
EP3986417A1 (fr)	2022-04-27	Sphingolipides pour produire des lymphocytes t cd4+ régulateurs
JP3520084B2 (ja)	2004-04-19	多発性硬化症を含めた炎症の治療におけるペプチドｔ及びその関連ペプチド類
Gao et al.	2014	Iminosugar derivative WGN-26 suppresses acute allograft rejection via inhibiting the IFN-γ/p-STAT1/T-bet signaling pathway
US20050191276A1 (en)	2005-09-01	Treatment of inflammatory bowel disease through induction of indoleamine 2.3-dioxygenase
JPH07316051A (ja)	1995-12-05	免疫抑制剤としてのベルベリン

Legal Events

Date	Code	Title	Description
1996-04-30	FZDE	Discontinued
2023-10-24	FZDE	Discontinued	Effective date: 19960430

CA2001790A1 - Compositions pharmaceutiques et leur utilisation - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=8146989

Family Applications (1)

Country Status (5)

Cited By (1)

Families Citing this family (11)

Family Cites Families (3)

Cited By (1)

Also Published As

Similar Documents

Legal Events